Author:
Wang Juan,Shi Dongni,Wang Yaochen,Zhang Xuanqi,Li Han,Wang Xihong,Luo Shufeng,Hu Lihan,Deng Jiashuai,Zhang Lin,Lau Chung Tai,Cheng Chung Wah,Han Fei,Li Ji,Wang Ping,Lyu Aiping,Bian Zhaoxiang,Zhang Xuan
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med 2017; 167(2): 112–121
2. Li M, Zhou B, Zhou L, Li L. Reporting quality of randomized controlled trials for the treatment of eczema with Chinese patent medicine based on the CONSORT-CHM Formulas 2017. Evid Based Complement Alternat Med 2020; 2020: 2949125
3. Zhang XJ, Wang YJ, Lu X, Ying PJ, Qian SY, Liang J, Zheng GQ. The quality of reporting of randomized controlled trials of HuatuoZaizao pill for stroke. Front Pharmacol 2023; 13: 1106957
4. Yu XW, Guo J, Yu W, Yan B, Du G, Wang H, Zhang J. Quality evaluation and consideration of randomized controlled clinical trials report on traditional Chinese medicine (TCM) treatment of prostate cancer. J Xinjiang Med Univ (Xinjiang Yi Ke Da Xue Xue Bao) 2022; 45(7): 776–779 (in Chinese)
5. Tian Y, Guo D, Peng W, Zhou P, Liu YC, Fan MX, Lu F. Evaluation of the clinical evidence-body of Chinese patent medicine in the treatment of essential hypertension. Chin J Hypertens (Zhonghua Gao Xue Ya Za Zhi) 2022; 30(10): 956–963 (in Chinese)